These are a group of rare genetic diseases where the body can't break down certain sugars called glycosaminoglycans properly. This causes the sugars to build up in different parts of the body, leading to various health problems.
Every report comes from a Lived member, sent anonymously.
Have you tried Enzyme Replacement Therapy for Mucopolysaccharidoses (MPS)?
Mucopolysaccharidoses (MPS) are a group of rare inherited diseases in which the body cannot properly break down glycosaminoglycans, long sugar chains that help build bone, cartilage, skin, the clear front of the eye (the cornea) and other connective tissue. Normally, enzymes inside cells recycle these chains. In MPS, one of those enzymes is missing or does not work, so the sugar chains build up in cells throughout the body and cause damage that worsens over time. Because the buildup happens almost everywhere, MPS affects many parts of the body at once. Common effects include short stature and skeletal changes, stiff joints, coarse facial features, an enlarged liver or spleen, hernias, repeated ear and breathing infections, sleep apnea, heart valve disease, hearing loss and clouding of the cornea. Some types also affect the brain, causing developmental delay, loss of skills and behavior changes, while others leave thinking and learning largely unaffected. MPS is an umbrella term rather than a single disease. There are seven main types, numbered I through IX (some numbers are no longer used), and several are better known by older names: Hurler syndrome (the severe form of MPS I), Hunter syndrome (MPS II), Sanfilippo syndrome (MPS III), Morquio syndrome (MPS IV), Maroteaux-Lamy syndrome (MPS VI) and Sly syndrome (MPS VII). Severity varies widely, even within one type. Many children seem typical at birth and develop symptoms over the first few years of life, while milder forms may not be recognized until later childhood or adulthood.
Each type of MPS is caused by a change (variant) in one gene that carries the instructions for a particular enzyme. The kind of gene change matters: variants that leave no working enzyme tend to cause earlier and faster-progressing disease, while those that leave some enzyme activity usually cause a milder course. Nothing a parent did during pregnancy causes MPS, and diet does not cause or prevent it. Most types are inherited in an autosomal recessive pattern. A child is affected only when they inherit a nonworking copy of the gene from both parents. Parents who each carry one copy usually have no symptoms, and each of their pregnancies has a 1 in 4 chance of an affected child. MPS II (Hunter syndrome) is the exception: it is X-linked, so it is passed from a mother who carries the gene to a son, and it occurs almost entirely in boys. Overall, about 1 in 25,000 babies born in the US has some form of MPS. The chance is higher when there is a family history of the condition or when parents are closely related.
MPS is often suspected when a child has a combination of features, such as slowing growth, stiff joints, coarse facial features, an enlarged abdomen, hernias, frequent ear or breathing infections, or developmental delay. Because each of these is common on its own, the pattern is what raises concern, and diagnosis is often delayed. A urine test that measures glycosaminoglycans is usually an early step, since high levels suggest MPS. The diagnosis is confirmed with an enzyme test on blood or other cells that shows which enzyme is low, and therefore which type of MPS is present. Genetic testing identifies the specific gene variant, which helps predict how the disease may progress, guides treatment choices and allows relatives to learn whether they are carriers. MPS I is on the list of conditions the US Department of Health and Human Services recommends for newborn screening, but each state decides whether to screen for it, so a typical newborn screen does not rule out every type. A positive newborn screen is followed by an enzyme test to confirm or exclude the diagnosis. Families with a known history can have prenatal testing or carrier testing, ideally with the help of a genetic counselor.
There is no cure for MPS, but treatment can slow some forms of damage, ease symptoms and improve daily function. Every option works best when it is started early, ideally before symptoms are advanced, because much of the damage MPS causes cannot be reversed. Care is usually coordinated by a metabolic or genetics specialist alongside a team that may include heart, lung, bone, ear, eye and brain specialists. Enzyme replacement therapy (ERT) supplies a manufactured version of the missing enzyme through an intravenous infusion, usually every week, for life. It is available for MPS I, II, VI and VII and for type A of MPS IV; examples include laronidase (Aldurazyme) for MPS I and idursulfase (Elaprase) for MPS II. ERT can shrink an enlarged liver and spleen and improve walking ability and joint movement, but it does not cross from the blood into the brain, so it does not treat the effects on thinking and development, and it has limited effect on bone growth and the eyes. Infusions are time-consuming and very expensive, and allergic reactions can occur, so the first infusions are given with medical monitoring. For the brain-related form of MPS II, tividenofusp alfa (Avlayah), an enzyme designed to cross into the brain, received accelerated approval from the US Food and Drug Administration in 2026 for children who do not yet have advanced neurologic impairment. The approval rests on a drop in a marker of the disease in spinal fluid; whether it preserves development over the long term is still being confirmed. A stem cell transplant (from bone marrow or umbilical cord blood) gives the body donor cells that make the enzyme for the rest of life. It is the established treatment for the severe form of MPS I (Hurler syndrome) when done in early childhood, and because donor cells can reach the brain, it can help preserve development, although results vary. It is a high-risk procedure that needs a matched donor, and it does not correct skeletal or eye problems. It is used more selectively in other types. Gene therapies are being studied in clinical trials but are not yet a standard option. Much of everyday care treats specific complications: physical therapy to keep joints moving, removing tonsils and adenoids or using breathing support for sleep apnea, surgery for hernias, carpal tunnel syndrome or narrowed spinal canal, a shunt to drain excess fluid around the brain, and corneal transplants for clouded vision. For MPS IV, surgery to stabilize the bones at the top of the neck can prevent life-threatening spinal cord injury.
MPS is progressive, but its course depends heavily on the type and on how much enzyme the body still makes. In severe forms that affect the brain, such as untreated Hurler syndrome, the severe form of Hunter syndrome and Sanfilippo syndrome, children often develop typically at first and then lose skills such as speech and walking, and life is usually shortened to childhood or the teenage years. In milder forms and in types that spare the brain, such as Morquio and Maroteaux-Lamy syndromes, people usually have typical intelligence and may live into adulthood, though joint, bone, breathing and heart problems often limit mobility and stamina over time. Early treatment can change this picture, particularly for those diagnosed before symptoms appear. Daily life usually involves a regular schedule of appointments, and for people on ERT, regular infusions that take several hours. Regular monitoring typically includes heart ultrasounds, breathing and sleep studies, hearing and eye exams, imaging of the spine and joints, and developmental assessments, so that complications can be treated before they cause lasting harm. Children often benefit from physical and occupational therapy, mobility aids and school support, and families often benefit from genetic counseling, social work and connection with other MPS families. One safety point affects almost everyone with MPS: anesthesia carries a high risk of breathing and airway complications, because the airway is often narrowed, the neck may be stiff or unstable and the heart may be affected. Any surgery, scan under sedation or dental procedure should be planned in advance with a team experienced in MPS, ideally coordinating several procedures under one anesthetic when possible.
Ask for an evaluation if a child has several features that point toward MPS, such as slowing growth, stiff joints, an enlarged abdomen, hernias, frequent ear or breathing infections and delayed or lost developmental skills, or if MPS runs in the family and you are planning a pregnancy. For someone already diagnosed, contact the care team promptly about new or louder snoring or pauses in breathing during sleep, new headaches, vomiting or sleepiness that could mean fluid pressure on the brain, a loss of skills, or new weakness, numbness, clumsiness or changes in walking, which can signal pressure on the spinal cord. Let the team know well before any planned procedure that needs anesthesia. Call 911 if, during an enzyme infusion or in the 24 hours after it, the person has trouble breathing, swelling of the throat or tongue, widespread hives or faintness, which can be signs of a severe allergic reaction.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Mucopolysaccharidoses (MPS) is like, what's helped you, or ask the community a question.